22 Mar 2023

Public disclosure of inside information in accordance with article 17(1) of Regulation (EU) No.  596/2014 on market abuse (Market Abuse Regulation).

London, UK, 22 March 2023: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI),  a leading, clinical-stage AI-enabled drug discovery and development company, today announces the  appointment of Marcello Damiani to its Board of Directors. His official appointment will be confirmed by the  Company’s Annual General Meeting of Shareholders, which will be held on 4 May 2023. Marcello will act as  an Independent Non-Executive Director of the Company.  

Dr. François Nader, Chairman of BenevolentAI, said: “We are pleased to welcome Marcello to our Board  as a Non-Executive Director. Drawing from his senior executive leadership experience at global organisations  such as Moderna and bioMérieux, Marcello offers a unique perspective and understanding of innovation in the  technology and biotech sectors. His experience will further strengthen the existing diversity and knowledge of  our Board as BenevolentAI continues to execute its ambitious growth strategy.” 

Marcello Damiani, said: “Technologies such as artificial intelligence offer huge promise to unlock complex  biology and uncover new medicines for a broad range of debilitating diseases. I am delighted to work alongside  BenevolentAI’s Board of Directors and leadership team to deliver on this promise and, in so doing, deliver a  new generation of transformative medicines to patients.” 

Joanna Shields, Chief Executive Officer and Board Director of BenevolentAI, said: “BenevolentAI is, at  its core, a technology development company with a mission to understand complex disease biology and enable  scientists to make novel discoveries. Marcello’s expertise in driving innovation in biopharma will be an  invaluable addition to our Board as we continue to scale the impact of our platform and AI tools.”  

Marcello has over 25 years of experience in senior executive positions in both private and publicly listed companies in the aerospace, high-tech and biotech industries. He is the former Chief Digital and Operational  Excellence Officer of Moderna Inc. (Nasdaq: MRNA), where he built the technology, processes, and digitisation landscape required to advance a new class of medicines based on mRNA science. Before joining Moderna in  2015, he served as Sr. Vice President & group CIO at bioMérieux from 2010 to 2015, having joined in 2009 as  Executive Director, IT Global Infrastructure services. 

Marcello holds an MBA from TRIUM, an MSc in Information Systems Architecture from the University of Toulouse, France and a BSc in Computer Science from the University of Toulouse, France. He also serves on  the Board of Cellarity, a biotech company based in Cambridge, MA. 


Fleur Wood – VP Investor Relations  
T: +44(0) 203 781 9360 

Rajin Kang - VP Communications 
T: +44(0) 203 781 9360 
FTI Consulting: 
Ben Atwell/Simon Conway/Victoria Foster Mitchell 
T: +44 203 727 1000 

About BenevolentAI 

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers BenevolentAI’s in-house drug pipeline and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Forward-looking Statements  

This release may contain forward-looking statements. Forward-looking statements are statements that are not  historical facts and may be identified by words such as "plans", "targets", "aims", "believes", "expects",  "anticipates", "intends", "estimates", "will", "may", "should" and similar expressions. Forward-looking  statements include statements regarding objectives, goals, strategies, outlook and growth prospects; future  plans, events or performance and potential for future growth; economic outlook and industry trends;  developments in BenevolentAI’s markets; the impact of regulatory initiatives; and/or the strength of  BenevolentAI’s competitors. These forward-looking statements reflect, at the time made, BenevolentAI’s  beliefs, intentions and current targets/aims. Forward-looking statements involve risks and uncertainties  because they relate to events and depend on circumstances that may or may not occur in the future. The  forward-looking statements in this release are based upon various assumptions based on, without limitation,  management's examination of historical operating trends, data contained in BenevolentAI’s records, and third party data. Although BenevolentAI believes these assumptions were reasonable when made, these  assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and  other important factors which are difficult or impossible to predict and are beyond BenevolentAI’s control.  Forward-looking statements are not guarantees of future performance, and such risks, uncertainties,  contingencies and other important factors could cause the actual outcomes and the results of operations,  financial condition and liquidity of BenevolentAI or the industry to differ materially from those results expressed  or implied by such forward-looking statements. The forward-looking statements speak only as of the date of  this release. No representation or warranty is made that any of these forward-looking statements or forecasts  will come to pass or that any forecast result will be achieved.

Back to press releases and in the media